S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
Log in
LON:SAR

Sareum Holdings plc (SAR.L) Share Forecast, Price & News

GBX 1.43
+0.01 (+0.49 %)
(As of 11/30/2020 04:20 PM ET)
Add
Compare
Today's Range
1.36
Now: GBX 1.43▼
1.53
50-Day Range
0.94
MA: GBX 1.61▼
2.34
52-Week Range
0.03
Now: GBX 1.43▼
3.09
Volume7.80 million shs
Average Volume24.65 million shs
Market Capitalization£46.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sareum Holdings plc engages in the discovery and development of therapeutic drugs to treat cancer and autoimmune diseases. It develops therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.50 out of 5 stars


Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolLON:SAR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.sareum.co.uk
Phone+44-1223-497700
Employees2

Debt

Debt-to-Equity RatioN/A
Current Ratio10.06
Quick Ratio10.06

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales£47,204.00
Price / Sales991.31
Cash FlowGBX 0.09 per share
Price / Cash Flow15.23
Book ValueGBX 0.10 per share
Price / Book14.32

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares3,267,719,936
Market Cap£46.79 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 1.43
+0.01 (+0.49 %)
(As of 11/30/2020 04:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAR News and Ratings via Email

Sign-up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sareum Holdings plc (SAR.L) (LON:SAR) Frequently Asked Questions

How has Sareum Holdings plc (SAR.L)'s stock been impacted by Coronavirus (COVID-19)?

Sareum Holdings plc (SAR.L)'s stock was trading at GBX 0.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SAR stock has increased by 369.5% and is now trading at GBX 1.43.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Sareum Holdings plc (SAR.L)?

Wall Street analysts have given Sareum Holdings plc (SAR.L) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sareum Holdings plc (SAR.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Sareum Holdings plc (SAR.L)'s key competitors?

Some companies that are related to Sareum Holdings plc (SAR.L) include Allergy Therapeutics plc (AGY.L) (AGY), Trilogy International Partners Inc. (TRL.TO) (TRL), NanoViricides (NNVC), Futura Medical plc (FUM.L) (FUM), Cathay International Holdings Limited (CTI.L) (CTI), Avivagen Inc. (VIV.V) (VIV), China Pharma (CPHI), N4 Pharma Plc (N4P.L) (N4P), Antisense Therapeutics Limited (ANP.AX) (ANP), Bayer Aktiengesellschaft (BAYN.F) (BAYN), Mayne Pharma Group (MAYNF), Mayne Pharma Group Limited (MYX.AX) (MYX), Medical Developments International Limited (MVP.AX) (MVP), Opthea Limited (OPT.AX) (OPT) and Otsuka (OTSKY).
View all competitors.

What other stocks do shareholders of Sareum Holdings plc (SAR.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sareum Holdings plc (SAR.L) investors own include ReNeuron Group plc (RENE.L) (RENE), ValiRx plc (VAL.L) (VAL), Sierra Oncology (SRRA), Egdon Resources plc (EDR.L) (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum Limited (GKP.L) (GKP), (MOIL.L) (MOIL), Summit Therapeutics (SMMT), Rockhopper Exploration plc (RKH.L) (RKH) and Anglo Pacific Group plc (APF.L) (APF).

Who are Sareum Holdings plc (SAR.L)'s key executives?

Sareum Holdings plc (SAR.L)'s management team includes the following people:
  • Dr. Tim J. Mitchell, Founder, CEO & Exec. Director (Age 60, Pay $187.28k)
  • Dr. John C. Reader Ph.D., Founder, Chief Scientific Officer & Exec. Director (Age 53, Pay $183.72k)
  • Tony Bunn, Sec.

What is Sareum Holdings plc (SAR.L)'s stock symbol?

Sareum Holdings plc (SAR.L) trades on the London Stock Exchange (LON) under the ticker symbol "SAR."

How do I buy shares of Sareum Holdings plc (SAR.L)?

Shares of SAR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Sareum Holdings plc (SAR.L)'s stock price today?

One share of SAR stock can currently be purchased for approximately GBX 1.43.

How big of a company is Sareum Holdings plc (SAR.L)?

Sareum Holdings plc (SAR.L) has a market capitalization of £46.79 million and generates £47,204.00 in revenue each year. Sareum Holdings plc (SAR.L) employs 2 workers across the globe.

What is Sareum Holdings plc (SAR.L)'s official website?

The official website for Sareum Holdings plc (SAR.L) is www.sareum.co.uk.

How can I contact Sareum Holdings plc (SAR.L)?

Sareum Holdings plc (SAR.L)'s mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The company can be reached via phone at +44-1223-497700.

This page was last updated on 11/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.